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http://www.biomedcentral.com/1471-2288/13/87RESEARCH ARTICLE Open AccessScreened selection design for randomised phase
II oncology trials: an example in chronic
lymphocytic leukaemia
Christina Yap1*, Andrew Pettitt2 and Lucinda Billingham1,3Abstract
Background: As there are limited patients for chronic lymphocytic leukaemia trials, it is important that statistical
methodologies in Phase II efficiently select regimens for subsequent evaluation in larger-scale Phase III trials.
Methods: We propose the screened selection design (SSD), which is a practical multi-stage, randomised Phase II
design for two experimental arms. Activity is first evaluated by applying Simon’s two-stage design (1989) on each
arm. If both are active, the play-the-winner selection strategy proposed by Simon, Wittes and Ellenberg (SWE) (1985)
is applied to select the superior arm. A variant of the design, Modified SSD, also allows the arm with the higher
response rates to be recommended only if its activity rate is greater by a clinically-relevant value. The operating
characteristics are explored via a simulation study and compared to a Bayesian Selection approach.
Results: Simulations showed that with the proposed SSD, it is possible to retain the sample size as required in SWE
and obtain similar probabilities of selecting the correct superior arm of at least 90%; with the additional attractive
benefit of reducing the probability of selecting ineffective arms. This approach is comparable to a Bayesian
Selection Strategy. The Modified SSD performs substantially better than the other designs in selecting neither arm if
the underlying rates for both arms are desirable but equivalent, allowing for other factors to be considered in the
decision making process. Though its probability of correctly selecting a superior arm might be reduced, it still
performs reasonably well. It also reduces the probability of selecting an inferior arm.
Conclusions: SSD provides an easy to implement randomised Phase II design that selects the most promising
treatment that has shown sufficient evidence of activity, with available R codes to evaluate its operating
characteristics.
Keywords: Randomised Phase II, Selection Design, Screening Design, Play-the-Winner, Oncology, Moderate Sample
SizesBackground
In recent years, there has been an increase in the
number of new potential therapies for treatment for
chronic lymphocytic leukaemia. In this setting where
the number of patients is limited and there are several
potentially promising treatments, the selection of efficient
and reliable statistical methodologies to evaluate these
new treatments in Phase II is vital.* Correspondence: c.yap@bham.ac.uk
1MRC Midland Hub for Trials Methodology Research, College of Medical and
Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK
Full list of author information is available at the end of the article
© 2013 Yap et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orMotivating example
The design proposed in this paper is motivated by a trial
in Chronic Lymphocytic Leukaemia (CLL). CLL is a
cancer of the white blood cells in which there is an
excess number of poorly functioning lymphocytes in the
circulating blood. It is the most common adult leukaemia
in the Western World. The study population includes
patients with high risk CLL, incorporating those cancers
with the genetic defect of p53 deletion, as well as those
who have failed standard chemotherapy. Conventional
therapy is not curative and thus treatment options are
limited. There is no agreed standard care and there is
significant morbidity and mortality in this group of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CAM-PRED (alemtuzumab+high-dose methylprednisolone)
regimen and produced an impressive complete response
with complete bone marrow recovery rate, CR, of 23% [1].
However, effects were short-lived with median progression
free survival of only 7 months. There was also a high rate of
grade 3–4 infections and steroid-related toxicity.
Building on from the CAM-PRED trial [1], it was of inter-
est to investigate two potential new treatment regimens,
CAM-DEX (Alemtuzumab+Dexmethasone) and CAM-
DEX-REV (Alemtuzumab+Dexmethasone+Lenalidomide).
The primary efficacy (also known as activity in Phase
II setting) outcome of interest is complete response
rate with complete marrow recovery (where all signs
of leukaemia have disappeared) as defined by the
IWCLL response criteria [2]. Replacement of high
dose methylprednisolone (PRED) with oral steroids,
dexamethasone (DEX) in the first treatment, CAM-DEX, is
believed to reduce infection and steroid related toxicity
whilst maintaining efficacy. Lenolidomide is included in the
second treatment, CAM-DEX-REV, as it has established
activity in CLL and has a favourable toxicity profile. The
CAM medication is administered via the subcutaneous
route throughout the study as opposed to the CAM-PRED
trial where it was given intravenously for the first month
and then subcutaneously thereafter. The change is
proposed as subcutaneous administration is easier and
produces fewer side effects, whilst demonstrating compar-
able results. CAM-DEX is expected to be comparable to
CAM-PRED while CAM-DEX-REV is believed to produce
a higher complete response rate.
The absence of any effective standard therapy and the
limited number of available patients in this study popula-
tion led us to consider comparison to historical controls’
complete response rates, which in this case, is close to null
for patients that are left untreated or undergo palliative
care. In this trial, there are two new treatment regimens to
be evaluated. To improve patient comparability, we chose a
randomised trial design rather than conduct two separate
trials. There are various approaches that have been used for
Randomised Phase II Designs, namely Parallel Simon’s 2
stage Design [3], Simon-Wittes-Ellenberg Selection Strategy
(SWE) [4], Jung and George’s Randomised Phase II [5], typ-
ical methods in Phase III design with relaxed Type 1 and
Type 2 errors [6] and a Bayesian Selection Strategy [7,8].
In the approach with parallel Simon’s 2 stage, the
required number of patients for the first stage is first
randomised into each arm. If there is insufficient efficacy,
recruitment to the arm will stop, whilst if there is
sufficient efficacy, a further group of patients will be
recruited for the second stage. At the end of the trial,
if there is sufficient efficacy, the treatment arm will
be considered active. The advantage of using this design is
that it allows for early termination if it does not showpromising efficacy at the interim stage. If both arms
are shown to be active, an ad hoc decision can be
taken to select the arm with the highest complete
response rate. However, this would unfortunately be
an unplanned decision as we have not incorporated
the selection between arms in the design.
SWE [4] has grown in its popularity as an established
randomised Phase II methodology. The approach is
based on the statistical method of ranking and selection
and is not based on the conventional hypothesis testing.
It considers randomizing n patients to each of the
treatment arms through a single stage and picking
the winner, the arm with the largest estimated
response rate among them. This design is attractive as it is
very simple and only requires moderate sample sizes to
provide a high probability of correctly selecting a superior
treatment for further testing in Phase III when such a
treatment exists. However there are several disadvantages
with this design. Firstly, it controls the false negative rate,
but makes no attempt to control the false positive rate,
which in fact is always 100% [9]. In the case where both
arms have equal response rates, you would always be
(incorrectly) selecting one treatment as superior. It is only
appropriate in settings whereby it is not crucial that the
superior treatment arm is selected if the activity rates are
fairly similar. Secondly, it will also select an arm with the
highest response rate even if none of the arms give
response rates that are of clinical significance.
This led us to propose the Screened Selection Design
(SSD), which combines the two conventional Phase II
methodologies, Simon’s 2 stage and SWE, and aims to
improve and minimise the shortfalls of the two approaches.
In addition, a variant of this design, the Modified Screened
Selection Design also allows the user the flexibility to only
select the active treatment arm with the highest response
rate if the activity rate is greater than the other arm by a
specified clinically-relevant value (hence, reducing the
chance that you would select an inferior arm). This would
allow other criteria, e.g. safety and toxicity, quality of life or
secondary efficacy outcome measures to be considered in
the final selection process, which is generally what happens
in clinical practice when we see two very similar success
rates in treatments. A similar idea was proposed by Sargent
and Goldberg [10], which extends the SWE to consider
other factors when there is only a small difference between
the activity rates.
The remainder of the paper is organised as follows:
The Methods section describes the proposed design and
an alternative approach via a Bayesian selection strategy
[7]. This is followed by the Results section, which presents
a simulation study to evaluate the operating characteristics
of the proposed design, and compares it with the conven-
tional SWE and a Bayesian selection strategy approach. It
also presents a strategy for practical implementation of
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wide range of activity rates. This is followed by Discussion
and Conclusion.
Methods
Screened selection design (SSD)
The Screened Selection Design involves first applying
Simon’s two-stage design [3] in each of the two parallel
experimental arms, which allows for initial determination
of efficacy and early stopping for futility in any of the
arms. If there are an insufficient number of responses in
the first stage, recruitment will not continue for that
particular arm. Otherwise, the study proceeds to stage
2 to randomize further patients to each arm. The
second segment of the study involves the play-the-winner
selection strategy as proposed by Simon, Wittes and
Ellenberg [4], which only applies if results from both
arms are found to be positive. SSD will recommend
the treatment arm with the highest response rate. An
extension of the SSD, the modified SSD only selects the
treatment arm with the highest response rate if the activity
rate is greater by a specified clinically-relevant value.
In the CLL example, a desirable complete response
rate is 20%. If we were to apply the SWE design to this
trial, we would require 29 patients per treatment arm
to allow at least 90% chance of correctly selecting
the better arm when the superior arm is 15% higher
(i.e. 20% vs. 35%). In our proposed SSD, we opt to
keep the sample size the same as that in SWE at 29 per
arm, and explore its operating characteristics in comparison
to SWE using simulations (see Section 3).
With N set at 29 and desiring a CR rate of at least
20% for an active arm in comparison to an undesirable
CR rate of 1% or less (with only palliative care) and
nominal alpha and beta set at 0.05, 14 patients would be
randomized to each arm for the first stage in the Simon’s
two-stage design. If there is no CR, recruitment to the
particular arm will stop. Otherwise, if there is at least 1
CR, 15 additional patients will be accrued for a total of
29 patients. The null hypothesis that the CR rate is
undesirable at ≤ 1% will be rejected and the treatment
arm would be considered active if there are at least 2
out of 29 patients who had CR. This design yields an
exact type I error rate of 0.026, and a power of 0.951
for the first segment when the true CR rate is 20%.
(Note: This is one possible 2 stage design for N = 29
[11], which is also the optimal design under both
nominal alpha and beta constraints of 0.05.) If both
arms are active, SSD then selects the arm with the
highest response rate. This is illustrated in Figure 1.
The modified SSD incorporates an extra feature where in
the case when the observed rates of both effective arms are
fairly similar, e.g. less than a specified difference, say 5%,
we would not select either arm only based on the primaryoutcome measure. Other criteria can be considered to aid
the selection.
SSD inherited the attractive features of being able to
check for efficacy at the interim stage and only allowing
arms that have been shown to be effective to undergo
the selection stage to be considered for further testing.
In this way, there should be a higher probability that the
final selected arm is not only superior but also active.
Comparison to a Bayesian approach
We compare the performance of the SSD and Modified
SSD with the Bayesian Selection Strategy proposed by
Estey and Thall [7] via a simulation study in Section 3.
The working of the Bayesian Selection Strategy is similar
to that of the SSD in that the initial segment includes
checking for activity, allowing for early stopping for
futility, before selecting the superior arm. However, this
is approached from the Bayesian framework. The method
will compare the posterior probabilities of response for
patients in the trial on treatment A and B with data
using CAM-PRED in the CLL206 trial [1], denoted
treatment S. Using the same sample size of 29 per arm, we
apply this design to the CLL trial and evaluate its operating
characteristics.
The prior probability for the treatment S is taken as
beta (9,30) with 23% CR (i.e. 9 CRs and 30 non-CRs) [1].
We assume a prior for each experimental arm A and B
as beta (0.4615, 1.5385), which is a weakly informative
prior, that has the same mean (i.e. mean CR of 23%) as
treatment S in CAM-PRED but with a low equivalent
sample size of 2, as recommended in [12].
The Bayesian Selection Strategy (BSS) will stop the
trial if we are 90% sure that the experimental arm, E is
less responsive than treatment S by 3% (desirable CR for
E is at least 20%), i.e.
P θE < θS – 0:03 dataj Þ > 0:9ð
where θE and θS are the probabilities of response in
experimental arm (A or B) and treatment S respectively
and using the same notation as [12] with δ = − 0.03 and
π* = 0.9.
Using the above values for δ and π*, with implementation
of stopping rules after every cohort of 10 patients, this gives
rise to stopping boundaries of ≤ 0/10 and ≤ 1/20. An arm is
selected if it accrues to the maximum sample size of 29 and
has the highest observed CR rate. The stopping boundaries
are obtained using the Multc Lean software [12] and
could be altered to make them more or less protective by
changing the values of δ and π*.
A subtle difference to the working of SSD and BSS is
that in SSD we would require an arm to be deemed
effective (at least 2 CRs) before it is being allowed to
be in the competition to be selected amongst all the
Figure 1 Screened selection design. A flow diagram of the Screened Selection Design, as applied to the CLL trial with two randomised
treatment arms, CAM-DEX and CAM-DEX-REV, with 58 patients.
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the maximum sample size to be reached before the
selection process.
Results
Comparison of results to conventional SWE
We explored the operating characteristics of our proposed
designs, SSD and modified SSD, with 1 million replications,
and compared it with SWE and the Bayesian Selection
Strategy using a fixed sample size of 29 per arm for each of
these designs. The operating characteristics describe the
three designs’ average behaviour under various reasonable
clinical scenarios in terms of overall selection probabilities
of Arm A, Arm B or No Selection. The scenarios
included settings whereby both arms have either the
same or different response rates within a relevant range
that is applicable for the CLL trial.
No arm is selected for SSD if both arms are negative
after the 1st segment. This also applies to the Modified
SSD, but in addition, it also includes no selection of
arms when the observed difference is less than d units
(which is taken as 5% in this example). Probability of
selecting no arm for SWE is always 0, as it would
always select an arm even if both arms are ineffective
or equivalent. The results of the simulation study are
displayed in Table 1.
As expected, when the true CR rates are below clinical
significance (Scenarios 1 and 5), the performance of SSD
and Modified SSD are far superior to SWE as they
correctly select none of the arms most of the time
compared to 0% for SWE. Modified SSD does substantially
better by selecting neither arm based on the primary
endpoint when both CR rates are desirable but are thesame (Scenarios 3 and 4), with over 33% increase in
identifying arms that have less than 5% difference in
response rates. Pre-specified secondary criteria could
be used to select between the two active arms. It has the
lowest probability of selecting the inferior arm when the
CR rates of the two arms are different (in Scenarios 5–8).
In terms of correctly selecting an effective arm
which is superior (in Scenario 6–8), SSD is lower
than SWE in Scenario 6 where it loses 4.8% in the
first segment to selection of neither arms for inactivity.
However it is comparable to SWE when both arms are
active. Probability of correct selection for Modified SSD is
lower though it still performs reasonably well.
Comparison of results to a Bayesian selection design
From the simulation results in Table 1, the Bayesian
Selection design is comparable to that of SSD. It has a
higher probability of correctly selecting no arm when
both are inactive, but has a lower probability of correctly
selecting a superior arm compared to SSD. Its working
characteristics of Bayesian Selection Strategy can however
be altered by changing the values in (1) to make it more or
less protective against different error criteria. As in SSD, it
could be easily extended to incorporate selection of superior
arm only if it is greater than the other arm by d %.
From Table 2, we can observe that the sample size
required for the Bayesian Selection Strategy is generally
lower when the arms are ineffective compared to
SSD. However, in the case when the arms are effective,
SSD performs better in recruiting a higher mean number
of subjects. As expected, both approaches provide a
substantial reduction in mean sample size particularly
when the arms are inactive.
Table 1 Simulation study to evaluate and compare performance of SSD, Modified SSD, SWE and Bayesian selection
strategy
Scenario True CR (pA,pB) Simulated overall selection probabilities
SSD Modified SSD SWE Bayesian selection strategy
Arm A Arm B No Arm Arm A Arm B No Arm+ Arm A Arm B No Arm Arm A Arm B No Arm
1 (0.01,0.01) 0.025 0.025 0.949 0.025 0.025 0.950 (0.001) 0.500 0.500 0 0.013 0.013 0.974
2 (0.1,0.1) 0.455 0.454 0.091 0.311 0.311 0.379 (0.287) 0.500 0.500 0 0.383 0.383 0.234
3 (0.2,0.2) 0.500 0.498 0.002 0.320 0.320 0.359 (0.357) 0.500 0.500 0 0.490 0.490 0.019
4 (0.3,0.3) 0.500 0.500 0.000 0.334 0.335 0.331 (0.331) 0.500 0.500 0 0.500 0.500 0.001
5 (0.01,0.03) 0.023 0.167 0.810 0.021 0.164 0.815 (0.004) 0.315 0.685 0 0.012 0.094 0.894
6 (0.01,0.2) 0.002 0.950 0.048 0.001 0.947 0.051 (0.003) 0.003 0.997 0 0.002 0.864 0.134
7 (0.20,0.35) 0.100 0.900 0.000 0.042 0.805 0.154 (0.154) 0.099 0.901 0 0.104 0.894 0.002
8 (0.2,0.4) 0.047 0.953 0.000 0.017 0.897 0.086 (0.086) 0.046 0.954 0 0.049 0.950 0.001
The table displays a simulation study to evaluate the operating characteristics of Screened Selection Design (SSD) and Modified Screened Selection Design
(Modified SSD), and compare it to Simon-Wittes-Ellenberg Selection Strategy (SWE) and Bayesian Selection Strategy, based on 1 million replications. The overall
probabilities of selecting Arm A, selecting Arm B and selecting neither arm (No Arm) for each design under various scenarios are presented. Scenarios 1–4 denote
situations when the rates at both arms are the same, whereas Scenarios 5–8 denote situations when the rates are different. The values in bold indicate the correct
selection probabilities under specific scenario. CR: Complete Response rate, pA: true CR rate for Arm A, pB: true CR rate for Arm B. +The values in parenthesis for
Modified SSD indicate the probability that neither arm is selected based on the primary endpoint when the observed difference is less than the clinically-relevant
value of 5%. This then directs the decision making process to other additional clinical factors to choose between the two active arms.
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In practice, when a trial is designed using SSD, we would
assess the operating characteristics (OCs) under various
design parameters and reasonable clinical scenarios via
simulations (as in Table 1), and utilise these as a basis
for choosing design parameters that have desirable OCs.
The R code to evaluate the OCs for SSD is freely available
(see Additional files 1 and 2).
The focus so far has been based on a worked example
of a trial with 2 experimental arms which are believed to
have rates that are clinically desirable, but one having aTable 2 Mean number of subjects required in SSD/
Modified SSD compared to Bayesian selection strategy in
the CLL trial example
Scenario True CR (pA,pB) Average number of subjects
SSD/Modified SSD Bayesian selection
strategy
Arm A Arm B Arm A Arm B
1 (0.01,0.01) 16.0 16.0 11.1 11.1
2 (0.1,0.1) 25.6 25.6 21.2 21.2
3 (0.2,0.2) 28.3 28.3 26.7 26.7
4 (0.3,0.3) 28.9 28.9 28.4 28.4
5 (0.01,0.03) 16.0 19.2 11.1 13.5
6 (0.01,0.2) 16.0 28.3 11.1 26.7
7 (0.20,0.35) 28.3 29.0 26.7 28.8
8 (0.2,0.4) 28.3 29.0 26.7 28.9
The table displays the mean number of subjects required for the Screened
Selection Design (SSD)/Modified Screened Selection Design (Modified SSD)
and the Bayesian Selection Strategy, obtained from the same simulation study
as presented in Table 1. Number of subjects required in SWE is always 29 per
arm, whereas the other two approaches, allowing for early stopping due to
futility, have a lower mean number of subjects when the arms are not active.much more superior CR rate. In this example, the
undesirable rate, p0, is 1%, with CR in Arms A and B at
pA = 20% and pB = 35%. Next, let us consider the
performance of the SSD for different response rates with
various design parameters where the undesirable rates
p0 range from 1% to 65% and the response rates in the
experimental arms are at least 15% higher. Using the
same sample size as that required in SWE with alpha
constrained to a specified value, we evaluate the overall
probability of correctly selecting the superior arm.
A strategy we adopted is detailed below:
(1)First, we determine the sample size, n, that is
required in SWE for pA and pB. This can be easily
obtained from Table 3 in [4], clinfun package in R
[13] or specialist software packages such as PASS.
(2)Using the same sample size in (1), we aim to find
suitable alpha and beta to screen for activity in
each arm for the first segment of SSD with Simon’s
two-stage design.
(a)We choose to constrain alpha to at most 20% (i.e.
we are happy for a 20% or less chance of
incorrectly identifying a treatment as effective
when it is not).
(b)To find suitable r1 and r, we first start with
nominal beta = 0.05 and nominal alpha = 0.2, and
select the optimal 2-stage design with sample
size n. However, if no such design exists, go to (c).
(c)Keeping alpha at 20%, one can increase beta by
steps of 1% till you obtain a design with sample
size n.
(3)Evaluate the overall probability of correctly selecting
the superior arm.
Table 3 Sample size and overall probability of correctly selecting a superior arm in SSD for different response rates
based on 1 million replications
Scenario Undesirable
rate, p0
Desirable rates n Nominal alpha
(exact alpha)
Nominal beta
(exact beta)
First segment (Simon’s 2 stage) Overall probability
of correctly selecting
a superior arm
pA* pB r1/n1 r/n
1 1% 20% 35% 29 0.05 (0.026) 0.05 (0.049) 0/14 1/29 0.900
2 5% 20% 35% 29 0.2 (0.169) 0.06 (0.059) 0/18 2/29 0.901
3 10% 30% 45% 35 0.2 (0.187) 0.05 (0.049) 2/19 4/35 0.903
4 15% 30% 45% 35 0.2 (0.197) 0.15 (0.122) 5/28 6/35 0.903
5 20% 40% 55% 37 0.18 (0.177) 0.05 (0.048) 3/19 9/37 0.902
6 25% 40% 55% 37 0.2 (0.191) 0.14 (0.138) 4/22 11/37 0.902
7 30% 50% 65% 36 0.2 (0.160) 0.07 (0.070) 5/21 13/36 0.901
8 35% 50% 65% 36 0.2 (0.198) 0.2 (0.191) 9/24 14/36 0.900
9 40% 60% 75% 32 0.2 (0.159) 0.1 (0.100) 8/21 15/32 0.900
10 45% 60% 75% 32 0.2 (0.198) 0.21 (0.204) 12/25 16/32 0.900
11 50% 70% 85% 26 0.2 (0.161) 0.13 (0.128) 7/16 15/26 0.904
12 55% 70% 85% 26 0.2 (0.194) 0.23 (0.230) 10/20 16/26 0.903
13 60% 80% 95% 16 0.2 (0.163) 0.21 (0.209) 4/8 11/16 0.904
14 65% 80% 95% 16 0.2 (0.191) 0.36 (0.357) 7/10 11/16 0.901
p0 : response proportion of a poor drug.
pA : response proportion of Arm A.
pB : response proportion of Arm B.
alpha : probability of rejecting p ≤ p0 when this is true (exact alpha provided in parenthesis).
beta : probability of rejecting p ≥ pA* when this is true (exact beta provided in parenthesis).
pA is taken as the minimum response rate of a good drug.
n1 : no. of subjects required for Stage 1 in Simon’s 2 stage.
r1 : maximum number of successes in which will terminate trial.
r : maximum number of successes at the end of Stage 2 not to warrant further investigation.
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satisfies the (nominal) error constraints, is selected for the
fixed sample size of n for each scenario. The alpha and beta
rates are specific to each arm in the first segment, and not
for the trial as a whole. Following the strategy as described
above, if we have two experimental arms at 30% and 45%, a
sample size of 35 is required for SWE to obtain an overall
probability of correct selection of superior arm of at least
90%. Using n = 35 with undesirable rate assumed at 10%,
and setting nominal alpha and beta at 0.2 and 0.05
respectively, the optimal 2-stage design is r1/n1 = 2/19
and r/n = 4/35. This gives an overall probability of
correctly selecting the superior arm as 0.903 for SSD. This
is given as Scenario (3) in Table 3, along with other
scenarios of different rates of p0, pA and pB.
The results from Table 3 demonstrate one of the most
appealing properties of SSD. We are able to retain
the sample size as required in SWE, and still be able
to obtain at least 90% probability of correctly selecting the
superior arm, with the added benefit of screening out
inactive arms (alpha ≤ 0.2).
Table 3 provides a reference to possible Screened
Selection Designs that can be used for different response
rates. They are examples rather than defaults. As noted
earlier, it is possible to choose different alpha and beta(and hence different r1 and r) for the same sample size,
as is relevant to a particular trial.
Discussion
We proposed an easy to implement randomised Phase II
design which performs a dual task; to first evaluate activity
before selecting the most promising treatment regimen
for further testing in Phase III, for moderate sample sizes.
As this design builds on the existing selection strategy
by [4], it is particularly useful in settings where only
limited number of subjects is available. If however, the pool
of patients is much larger, we could consider a typical Phase
III type design but with relaxed alpha and beta errors [6]
with alpha (two-sided) and beta of 0.2. This would require
182 patients (91 per arm) to determine if there is a
difference between the independent proportions of 0.2
and 0.35 based on Fisher’s Exact test. If a test is carried
out with one-sided alpha, this would require 126 patients
(63 per arm), which is still a much larger sample size
compared to designs using selection strategy, as in SWE.
Conventional statistical designs require much larger
number of patients, as they select a treatment as
superior only when the observed data are incompatible
with the hypothesis that the treatments are equal. In the
approach suggested by Jung & George [5], they proposed
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selecting the superior arm based on hypothesis testing.
For a fixed probability of correctly selecting the superior
treatment, this would again require a larger sample size
than our proposed design of SSD based on selection
theory. Alternatively, for a fixed sample size, the probability
of correctly selecting the superior treatment is substantially
higher with Modified SSD compared to Jung and George’s
design. This can be illustrated by considering Example 4
from their paper [5] which for a fixed sample size of 45
patients designed to compare hypothesized response rates
of 15% vs 35% the probability of correctly selecting the
superior treatment when the true rates are 25% vs 45% is
0.927 with modified SSD compared to 0.639 with Jung
and George.
On the other hand, selection theory designs always
selects a treatment as superior, even if they are actually
equivalent. This design flaw is carried over into the SSD
design so that if both treatments have rates that are above
undesirable activity but are identical (Scenarios 2–4 in
Table 1) then the design will still select an arm that is
superior. With the addition of a decision rule of observing
a superior difference of at least 5%, the Modified SSD
does better by at least 28% in such settings, in
selecting neither arms based on the primary outcome.
Instead, it directs the decision to additional factors to
determine the selection of the superior arm. There is
however still a reasonably high chance that the SSD
and Modified SSD will select an arm as superior even
if both arms are equivalent or similar, but it is
important to note that the objective of such randomised
selection trials is not to make a definite conclusion about
the superiority of a treatment compared to another. The
primary aim of such designs is to ensure that there is a
low probability that the inferior treatment will be carried
forward to a phase III trial.
The factors that determine the choice between SSD
and Modified SSD depend on the clinical setting. Both
are designed to remove ineffective arms before selecting
the superior one. In the setting where it is not crucial
for the chosen arm to be truly superior, and in fact could
be slightly inferior, SSD can be used. However, in the
case where it is important that there is a high probability
that the selected arm is superior, it would be more
appropriate to use Modified SSD. By allowing no arm to
be selected when the rates are fairly similar based on
the primary outcome measure, this design enables
other pre-planned clinical criteria (as stated in protocol)
that are relevant to the decision process, to make the
distinction between the two active arms. This is similar to
settings when we would consider choosing either SWE or
Sargent-Goldberg screening design [10].
Using the same sample size as in SWE, the proposed
approach has the advantage of substantial reduction inthe probability of incorrectly selecting an ineffective arm
whose rates are not clinically significant (both SSD and
Modified SSD) or when no true difference exists
between the arms (Modified SSD). As we have observed
from the simulation results in the CLL example, the
probability of correctly selecting a superior arm is very
similar in the SSD and SWE when both arms are effective
(i.e. CR ≥ 20%). Whilst SWE only selects the superior arm,
SSD only selects the superior arm if it has been shown to
be effective. Modified SSD goes a step further from SSD
by selecting an effective, superior arm only if it is shown
to be superior by a difference of at least d % based on the
primary endpoint.
The SSD is comparable to the Bayesian approach
proposed by Estey and Thall, though the latter has a
greater flexibility in intra-arms stopping boundaries.
However, it is possible to extend the design of SSD to
incorporate more flexible stopping boundaries for
futility in the first segment, for instance, using a three
stage design which allows for two interim evaluation
[14] if this is appropriate. Generally, a two stage
design is more common to reduce disruption to the
enrolment of the trial while an interim analysis is
being carried out.
We illustrated our proposed design for use in trials
where there are two potential treatment regimens that
have response rates that are hypothesized to be at least
15% better the historical control rates, which is typically
used in Phase II trial designs. However, in settings whereby
the difference in the rate for the inferior treatment
arm and the undesirable rate is small, a much larger
sample size might be required for Simon’s 2 stage in
the first segment of SSD, within a set constraint of
alpha and beta levels. In such cases, it might be
useful to consider sample size as the maximum of the
two sample sizes required for the two segments and adjust
it accordingly by examining the operating characteristics
of the design.
The SSD or Modified SSD is most appropriate when it
is hypothesized, before the trial, that the potential treat-
ment regimens are effective. If one or neither treatment
is believed to be effective, it is unlikely that the trial will
move to the selection phase. Liu et al. [15] proposed a
comparable design of combining parallel single arm
single stage Phase II to screen for activity before selection
with SWE. Besides the obvious difference that a single
stage is used in theirs compared to a two stage design in
SSD, the other main difference is that they considered
one of their experimental treatment regimens to have
a rate as undesirable as that in the historical controls.
They allowed for Bonferroni correction of the type 1
error with alpha set at 0.025 for two treatment arms
and power of 0.90. In their example, if CR rate for
Arm A is 5% and Arm B is 20% with undesirable and
Yap et al. BMC Medical Research Methodology 2013, 13:87 Page 8 of 9
http://www.biomedcentral.com/1471-2288/13/87desirable rates at 5% and 20% respectively, there is
only a 2.5% (alpha =0.025) chance that Arm A will be
deemed positive in the first segment before moving to
the 2nd segment for selection, whilst there is a 90%
chance (beta = 0.1) that Arm B will be deemed positive.
Hence, it is very unlikely that both arms will be positive.
In most cases, only Arm B moves to the second segment
and is selected by default. Hence, the selection strategy is
seldom utilised and the example therefore does not
fully illustrate the attractive features of such a design
whose intention is select a superior arm after screening
independent arms for activity.
Despite the use of randomization and the independent
evaluation of activity in each treatment, results from
any trial using a SSD or Modified SSD should not be
considered definitive. The aim of such a trial design
is to select the best active experimental treatment
arm to take through to a phase III setting where a
formal comparison against the best standard of care
will enable decisions regarding the treatment of future
patients.
Our proposed design can be used or modified to suit a
variety of situations. We have considered Simon’s two stage
design to evaluate activity; however, we could also consider
tolerability in the first segment to determine that the drug
is safe before selecting based on activity. The design
can be easily extended to more than 2 arms. Future
work includes adapting the design for time to event
endpoints, such as progression free survival or overall
survival [16,17] and for evaluating joint outcomes of
tolerability and activity [18].
Conclusion
In conclusion, the proposed approach provides a simple
and easy to implement randomised Phase II design to
select an active and most promising treatment regimen
for further testing in Phase III with moderate sample
sizes. Simulation studies have demonstrated that it is
possible to use the same sample size in SSD as required
in SWE, whilst maintaining adequate probability of
correctly selecting a superior arm, with the important
benefit of reducing the probability of incorrect selection
of ineffective arms. Hence, we would strongly recommend
considering the use of SSD whenever a selection strategy
is appropriate for randomised Phase II design, particularly
if there is no strong evidence that the experimental arms
are definitely active.Additional files
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